Discovery and biosynthesis of karnamicins as angiotensin converting enzyme inhibitors

Nat Commun. 2023 Jan 13;14(1):209. doi: 10.1038/s41467-023-35829-1.

Abstract

Angiotensin-converting enzyme inhibitors are widely used for treatment of hypertension and related diseases. Here, six karnamicins E1-E6 (1-6), which bear fully substituted hydroxypyridine and thiazole moieties are characterized from the rare actinobacterium Lechevalieria rhizosphaerae NEAU-A2. Through a combination of isotopic labeling, genome mining, and enzymatic characterization studies, the programmed assembly of the fully substituted hydroxypyridine moiety in karnamicin is proposed to be due to sequential operation of a hybrid polyketide synthase-nonribosomal peptide synthetase, two regioselective pyridine ring flavoprotein hydroxylases, and a methyltransferase. Based on AlphaFold protein structures predictions, molecular docking, and site-directed mutagenesis, we find that two pyridine hydroxylases deploy active site residues distinct from other flavoprotein monooxygenases to direct the chemo- and regioselective hydroxylation of the pyridine nucleus. Pleasingly, karnamicins show significant angiotensin-converting enzyme inhibitory activity with IC50 values ranging from 0.24 to 5.81 μM, suggesting their potential use for the treatment of hypertension and related diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors* / pharmacology
  • Antihypertensive Agents*
  • Mixed Function Oxygenases
  • Molecular Docking Simulation
  • Pyridines

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • karnamicin
  • Antihypertensive Agents
  • Pyridines
  • Mixed Function Oxygenases